Showing results (21-30 of 51) with videos related to
Sort By:
Pageof 6
Future Oncology (London, England)|January 20, 2022
Overall survival in the real-world and clinical trials: a case study validating external controls in advanced melanomaJames Signorovitch, Andriy Moshyk, Jing Zhao, et al.BMC Health Services Research|January 25, 2017
Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrencesTereza Lanitis, Robert Leipold, Melissa Hamilton, et al.Clinical Therapeutics|February 29, 2016
Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of RecurrenceTereza Lanitis, Robert Leipold, Melissa Hamilton, et al.Pharmacoeconomics - Open|August 25, 2022
Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067Timothy Baker, Helen Johnson, Srividya Kotapati, et al.Heart, Lung & Circulation|May 20, 2014
Seven years experience of a nurse-led elective cardioversion service in a tertiary referral centre: an observational studyPeter T Moore, Gerald C Kaye, Melissa Hamilton, et al.Stroke|April 28, 2017
Ischemic Stroke in Nonvalvular Atrial Fibrillation at Warfarin Initiation: Assessment via a Large Insurance DatabasePing G Tepper, Xianchen Liu, Melissa Hamilton, et al.Thrombosis and Haemostasis|August 20, 2016
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysisGregory Y H Lip, Allison Keshishian, Shital Kamble, et al.Future Oncology (London, England)|February 7, 2022
Treatment patterns and outcomes following disease progression on anti-PD-1 therapies for advanced melanomaBeth L Nordstrom, Melissa Hamilton, Jenna M Collins, et al.Current Medical Research and Opinion|September 26, 2017
Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillationShuqian Liu, Xiaoyan Li, Qian Shi, et al.American Journal of Therapeutics|March 8, 2013
Venous thromboembolism prophylaxis and clinical consequences in medically ill patientsOnur Baser, Xianchen Liu, Hemant Phatak, et al.Pageof 6